Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report
oleh: Sho Mitsuya, MD, Masahiro Arai, MD, Kiyoe Kanaoka, MD, Tomoya Funamoto, MD, Hiroyuki Tsuji, MD, Kenjiro Tsuruoka, MD, PhD, Ninso Matsunaga, MD, Takahiko Nakamura, MD, Yosuke Tamura, MD, PhD, Masafumi Imanishi, MD, PhD, Soichiro Ikeda, MD, PhD, Akihisa Imagawa, MD, PhD, Yasuhito Fujisaka, MD, PhD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2024-02-01 |
Deskripsi
Osimertinib administration has been approved as an adjuvant treatment after complete surgical resection in patients with EGFR-mutated NSCLC. This article presents the first report of life-threatening postoperative osimertinib-induced interstitial lung disease. An 83-year-old male patient underwent right upper lobectomy (pathologic stage IIA) and osimertinib (80 mg/d) was initiated on postoperative day 75. On day 44 of osimertinib administration, chest computed tomography revealed diffuse ground-glass opacities; accordingly, osimertinib-induced interstitial lung disease was diagnosed. Steroid pulse therapy was initiated using a high-flow nasal cannula to treat dyspnea and hypoxemia, rapidly improving the respiratory status and imaging findings; moreover, the patient’s clinical course was excellent. This case report suggests that the postoperative occurrence of severe osimertinib-induced interstitial lung disease is a crucial factor that must be considered in patient decision-making regarding perioperative treatment.